Biogen Inc (MIL:1BIIB)
€ 210.6 -0.2 (-0.09%) Market Cap: 30.89 Bil Enterprise Value: 36.29 Bil PE Ratio: 28.79 PB Ratio: 2.19 GF Score: 55/100

Biogen Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 03:00PM GMT
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. Good morning from the virtual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm the senior large-cap biotech analyst, and it's my pleasure to introduce our next company, Biogen, and CEO Michel Vounatsos.

Please note that following this presentation, we will have a Q&A session right here in this Zoom room where you'll also be able to submit your questions via the little blue Ask A Question button in your conference portal. So with that, Michel, thanks for being here today, and let me turn things over to you.

Michel Vounatsos
Biogen Inc. - CEO & Director

Thank you, Cory. Good day, everyone, and thank you for joining the Biogen session. I would like to point out that we'll be making some forward-looking statements, which are based on our expectation and beliefs. These statements are subject to risks and uncertainties. So therefore, I encourage you to consult the risk factors discussed in our SEC filing.

I would like to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot